Clinical focus Artelo Biosciences is a clinical stage pharmaceutical company targeting lipid-signaling pathways to treat cancer, pain, dermatologic, and neurological conditions, indicating opportunities to position partnerships or trials with oncology and supportive care channels.

FABP5 platform Lead FABP5 inhibitor ART26.12/ART26.12 and ART27.13 programs present multipurpose therapeutic potential; explore licensing, co-development, or joint ventures with biopharma seeking lipid-signaling targets or cachexia/pain management indications.

Trial activity Active and upcoming studies such as Cancer Appetite Recovery Study (CAReS) and neuropathic pain exploration suggest potential for investigator-initiated trials or trial supply partnerships, as well as patient support program collaborations.

Strategic partnerships Recent collaboration with ScienceMachine to accelerate FABP5 programs signals openness to data-driven partnerships, AI-enabled drug development, and platform integrations that could extend to CROs, analytics providers, or digital health colocations.

Investor and outreach Active investor engagement and conference participation indicate a need for sponsor-ready materials and strategic outreach to funders and strategic buyers, presenting opportunities for sponsored research deals or capital-efficient collaboration.